The earnings call highlighted strong revenue and volume growth, the successful launch of new products, and increased pharma services revenue. However, challenges such as the loss of a high ASP account, slower ASP gains, and increased expenses indicate areas of concern. While the company shows positive operational momentum, financial challenges balance the sentiment.

Company Guidance

During Exagen Inc.'s Q3 2025 earnings call, the company reported a robust 19% year-to-date revenue growth, attributed to an 8% increase in testing volume and a 9% rise in average selling price (ASP). The company launched anti-PAD4 antibodies, its second rheumatoid arthritis biomarker set for the year, although its immediate revenue impact is expected to be modest. Exagen is on track to achieve $65 million to $70 million in revenue for 2025, with the potential to be cash flow positive at the high end of this range, though sustained cash flow positivity might be delayed until 2026 due to ASP challenges. The company also highlighted a significant revenue increase in its Pharma Services business, generating $780,000 this quarter, and continues to see a strong order backlog of $3.5 million. Despite losing a high ASP direct bill account, Exagen's revenue has benefited from volume growth, and the company continues to work on ASP expansion through revenue cycle management, appeals, and payer education efforts.

Record Quarter Revenue

Fourth quarter revenue of $17.2 million was the highest quarter in Exagen's history, marking a nearly 40% increase over the third quarter of 2024, even considering over $1 million in downside revenue adjustments in Q3 of last year.

Strong Volume Growth

Q3 testing volume was the highest ever recorded for a third quarter period, with AVISE CTD testing volume up 15% from Q3 of last year and almost 2% sequentially.

Expansion of Pharma Services Revenue

Pharma Services revenue increased to $780,000 in the third quarter, with a year-to-date total of $1.2 million compared to about $100,000 in 2024.

Launch of New Rheumatoid Arthritis Biomarkers

Successfully launched assays for the detection of anti-PAD4 antibodies, differentiating Exagen's rheumatoid arthritis offering.

Continued ASP Expansion

Trailing 12-month ASP for AVISE CTD reached $441, a 9% increase year-over-year.

Exagen (XGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

XGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 23, 2026	2025 (Q4)	-0.18 / -	-0.2	―	―	―
Nov 04, 2025	2025 (Q3)	-0.16 / -0.31	-0.28	-10.71% (-0.03)	―
Jul 29, 2025	2025 (Q2)	-0.15 / -0.21	-0.16	-31.25% (-0.05)	―
May 05, 2025	2025 (Q1)	-0.20 / -0.20	-0.19	-5.26% (-0.01)	―
Mar 11, 2025	2024 (Q4)	-0.26 / -0.20	-0.31	35.48% (+0.11)	―
Nov 12, 2024	2024 (Q3)	-0.29 / -0.28	-0.31	9.68% (+0.03)	―
Aug 05, 2024	2024 (Q2)	-0.34 / -0.16	-0.28	42.86% (+0.12)	―
May 13, 2024	2024 (Q1)	-0.36 / -0.19	-0.44	56.82% (+0.25)	―
Mar 18, 2024	2023 (Q4)	-0.43 / -0.31	-0.83	62.65% (+0.52)	―
Nov 13, 2023	2023 (Q3)	-0.47 / -0.31	-0.47	34.04% (+0.16)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

XGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2025	$11.83	$10.77	-8.96%
Jul 29, 2025	$7.39	$8.45	+14.34%
May 05, 2025	$6.02	$6.25	+3.82%
Mar 11, 2025	$2.85	$3.37	+18.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Exagen Inc (XGN) report earnings?

Exagen Inc (XGN) is schdueled to report earning on Mar 23, 2026, After Close (Confirmed).

What is Exagen Inc (XGN) earnings time?

Exagen Inc (XGN) earnings time is at Mar 23, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is XGN EPS forecast?

XGN EPS forecast for the fiscal quarter 2025 (Q4) is -0.18.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing